Stock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings

Stock Track11-12

uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following positive analyst actions from major financial firms.

Wells Fargo analyst Yanan Zhu has maintained a Buy rating on uniQure, setting an ambitious price target of $60.00. This reaffirmation of confidence comes as Zhu continues to cover the Healthcare sector, with a particular focus on uniQure's potential in the gene therapy space. The bullish stance from Wells Fargo follows a similar move by Chardan Capital, which maintained its Buy rating on uniQure in the previous trading session.

These back-to-back positive analyst actions underscore the growing optimism surrounding uniQure's business model and future prospects. As a company known for its innovative gene therapy developments, uniQure continues to draw interest from investors and analysts alike. The maintained Buy ratings suggest that these financial experts see significant upside potential in uniQure's stock, likely driven by the company's progress in developing cutting-edge treatments for genetic disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138163270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138163270","market":"nz","top_or_hot":-1,"title":"Stock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings","media":"Stock Track","content":"<p>uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following positive analyst actions from major financial firms.</p>\n\n<p>Wells Fargo analyst Yanan Zhu has maintained a Buy rating on uniQure, setting an ambitious price target of $60.00. This reaffirmation of confidence comes as Zhu continues to cover the Healthcare sector, with a particular focus on uniQure's potential in the gene therapy space. The bullish stance from Wells Fargo follows a similar move by Chardan Capital, which maintained its Buy rating on uniQure in the previous trading session.</p>\n\n<p>These back-to-back positive analyst actions underscore the growing optimism surrounding uniQure's business model and future prospects. As a company known for its innovative gene therapy developments, uniQure continues to draw interest from investors and analysts alike. The maintained Buy ratings suggest that these financial experts see significant upside potential in uniQure's stock, likely driven by the company's progress in developing cutting-edge treatments for genetic disorders.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | uniQure NV Soars 5.71% Pre-market on Bullish Analyst Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following positive analyst actions from major financial firms.</p>\n\n<p>Wells Fargo analyst Yanan Zhu has maintained a Buy rating on uniQure, setting an ambitious price target of $60.00. This reaffirmation of confidence comes as Zhu continues to cover the Healthcare sector, with a particular focus on uniQure's potential in the gene therapy space. The bullish stance from Wells Fargo follows a similar move by Chardan Capital, which maintained its Buy rating on uniQure in the previous trading session.</p>\n\n<p>These back-to-back positive analyst actions underscore the growing optimism surrounding uniQure's business model and future prospects. As a company known for its innovative gene therapy developments, uniQure continues to draw interest from investors and analysts alike. The maintained Buy ratings suggest that these financial experts see significant upside potential in uniQure's stock, likely driven by the company's progress in developing cutting-edge treatments for genetic disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QURE","symbol_name":"uniQure N.V.","start_time":0,"source_url":"","article_id":"1138163270","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138163270","pubTimestamp":1762952608,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QURE":"uniQure N.V."},"translate_title":"股票追踪|uniQure NV盘前飙升5.71%，分析师评级看涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1},"content_text":"uniQure NV (QURE) shares are surging 5.71% in pre-market trading on Wednesday, building on the previous day's gains. The biotechnology company's stock is attracting investor attention following positive analyst actions from major financial firms.\nWells Fargo analyst Yanan Zhu has maintained a Buy rating on uniQure, setting an ambitious price target of $60.00. This reaffirmation of confidence comes as Zhu continues to cover the Healthcare sector, with a particular focus on uniQure's potential in the gene therapy space. The bullish stance from Wells Fargo follows a similar move by Chardan Capital, which maintained its Buy rating on uniQure in the previous trading session.\nThese back-to-back positive analyst actions underscore the growing optimism surrounding uniQure's business model and future prospects. As a company known for its innovative gene therapy developments, uniQure continues to draw interest from investors and analysts alike. The maintained Buy ratings suggest that these financial experts see significant upside potential in uniQure's stock, likely driven by the company's progress in developing cutting-edge treatments for genetic disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138163270","isCrawlerRequest":true}